Net income of ~$12-14 mln, which includes the impact of the ~$4 mln success-based regulatory milestone expense in the first quarter of 2012 related to UCERIS and a $10 mln expense for the success-based clinical milestone for RUCONEST in the fourth quarter.
Adjusted EBITDA of ~$29-32 mln.
Co is introducing its financial outlook for full year 2013 as follows:
Net income of approximately $50-54 mln.
Adjusted EBITDA of ~$73-79 mln.
*Co also announced it received FDA approval of UCERIS for the induction of remission in patients with active, mild to moderate ulcerative colitis.
1:30AM Santarus receives FDA approval of UCERIS for the induction of remission in patients with active, mild to moderate ulcerative colitis (SNTS) 11.28 : Co announces the FDA has approved UCERIS extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. The co expects to commence the commercial launch of UCERIS in March 2013.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM